88 related articles for article (PubMed ID: 18722685)
1. Plasma FGF-21 levels in type 2 diabetic patients with ketosis.
Li L; Yang G; Ning H; Yang M; Liu H; Chen W
Diabetes Res Clin Pract; 2008 Nov; 82(2):209-13. PubMed ID: 18722685
[TBL] [Abstract][Full Text] [Related]
2. Circulating obestatin levels in normal subjects and in patients with impaired glucose regulation and type 2 diabetes mellitus.
Qi X; Li L; Yang G; Liu J; Li K; Tang Y; Liou H; Boden G
Clin Endocrinol (Oxf); 2007 Apr; 66(4):593-7. PubMed ID: 17371480
[TBL] [Abstract][Full Text] [Related]
3. Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus.
Li K; Li L; Yang M; Zong H; Liu H; Yang G
Eur J Endocrinol; 2009 Sep; 161(3):391-5. PubMed ID: 19528204
[TBL] [Abstract][Full Text] [Related]
4. Mitiglinide treatment may decreases plasma fibroblast growth factor-21 levels in individuals with new-onset T2DM.
Wang B; Yang G; Yang M; Liao Y; Li Z; Boden G; Li L
Cytokine; 2012 Feb; 57(2):300-3. PubMed ID: 22129626
[TBL] [Abstract][Full Text] [Related]
5. [Expression of omentin in adipose tissues in obese and type 2 diabetic patients].
Cai RC; Wei L; DI JZ; Yu HY; Bao YQ; Jia WP
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(6):381-4. PubMed ID: 19567114
[TBL] [Abstract][Full Text] [Related]
6. Association between serum fibroblast growth factor 21 and diabetic nephropathy.
Jian WX; Peng WH; Jin J; Chen XR; Fang WJ; Wang WX; Qin L; Dong Y; Su Q
Metabolism; 2012 Jun; 61(6):853-9. PubMed ID: 22136913
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome.
Barutcuoglu B; Basol G; Cakir Y; Cetinkalp S; Parildar Z; Kabaroglu C; Ozmen D; Mutaf I; Bayindir O
Ann Clin Lab Sci; 2011; 41(4):390-6. PubMed ID: 22166511
[TBL] [Abstract][Full Text] [Related]
8. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus.
Chen WW; Li L; Yang GY; Li K; Qi XY; Zhu W; Tang Y; Liu H; Boden G
Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):65-8. PubMed ID: 17926232
[TBL] [Abstract][Full Text] [Related]
9. Admissions for diabetic ketoacidosis in ethnic minority groups in a city hospital.
Nyenwe E; Loganathan R; Blum S; Ezuteh D; Erani D; Palace M; Ogugua C
Metabolism; 2007 Feb; 56(2):172-8. PubMed ID: 17224329
[TBL] [Abstract][Full Text] [Related]
10. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on plasma omentin-1 levels in patients with type 2 diabetes mellitus.
Yan P; Li L; Yang M; Liu D; Liu H; Boden G; Yang G
Diabetes Res Clin Pract; 2011 Jun; 92(3):368-74. PubMed ID: 21458097
[TBL] [Abstract][Full Text] [Related]
11. High sensitive C-reactive protein, adiponectin, and urine albumin excretion rate in Chinese coronary artery disease patients with different glucose tolerance status.
Gui MH; Hong J; Lü AK; Chen Y; Shen WF; Li XY; Ning G
Chin Med J (Engl); 2008 Dec; 121(24):2509-16. PubMed ID: 19187587
[TBL] [Abstract][Full Text] [Related]
12. Acute hyperinsulinemia raises plasma interleukin-6 in both nondiabetic and type 2 diabetes mellitus subjects, and this effect is inversely associated with body mass index.
Ruge T; Lockton JA; Renstrom F; Lystig T; Sukonina V; Svensson MK; Eriksson JW
Metabolism; 2009 Jun; 58(6):860-6. PubMed ID: 19375766
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor-19: development, analytical characterization and clinical evaluation of a new ELISA test.
Stejskal D; Karpísek M; Hanulová Z; Stejskal P
Scand J Clin Lab Invest; 2008; 68(6):501-7. PubMed ID: 18609104
[TBL] [Abstract][Full Text] [Related]
14. Effect of Metformin on Fibroblast Growth Factor-21 Levels in Patients with Newly Diagnosed Type 2 Diabetes.
Fan H; Sun X; Zhang H; Liu J; Zhang P; Xu Y; Pan Q; Wang G
Diabetes Technol Ther; 2016 Mar; 18(3):120-6. PubMed ID: 26950284
[TBL] [Abstract][Full Text] [Related]
15. Serum FGF-21 levels in type 2 diabetic patients.
Cheng X; Zhu B; Jiang F; Fan H
Endocr Res; 2011; 36(4):142-8. PubMed ID: 21973233
[TBL] [Abstract][Full Text] [Related]
16. Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients.
Gastaldelli A; Casolaro A; Ciociaro D; Frascerra S; Nannipieri M; Buzzigoli E; Ferrannini E
Am J Physiol Endocrinol Metab; 2009 Jul; 297(1):E225-30. PubMed ID: 19417125
[TBL] [Abstract][Full Text] [Related]
17. [Effects of glucagon on plasma ghrelin level in type 2 diabetes mellitus].
Lin SD; Chen ZX; Lin CJ; Duan HY
Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(14):967-9. PubMed ID: 19671308
[TBL] [Abstract][Full Text] [Related]
18. Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy.
Terekeci HM; Senol MG; Top C; Sahan B; Celik S; Sayan O; Kucukardali Y; Ipcioglu O; Cagiltay E; Oktenli C; Ozata M
Exp Clin Endocrinol Diabetes; 2009 Mar; 117(3):119-23. PubMed ID: 19053023
[TBL] [Abstract][Full Text] [Related]
19. Beta-cell function and mass in type 2 diabetes.
Larsen MO
Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
[TBL] [Abstract][Full Text] [Related]
20. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity.
Mraz M; Bartlova M; Lacinova Z; Michalsky D; Kasalicky M; Haluzikova D; Matoulek M; Dostalova I; Humenanska V; Haluzik M
Clin Endocrinol (Oxf); 2009 Sep; 71(3):369-75. PubMed ID: 19702724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
